New Regulatory Regime For 8 Medical Items Under Drugs And Cosmetics Act

New Delhi : Adopting a proactive and sensitive approach to address the needs of the Indian Industry, the Union Ministry of Health & Family Welfare has taken a significant decision for ensuring continued access of eight regulated medical devices today.

The Ministry had earlier notified the following medical items to be regulated under the Drugs and Cosmetics Act which was to come into effect from 1st April, 2021 (as per S.O. 775(E) dated 08th February, 2019 under Medical Devices Rules 2017):

  1. All Implantable Medical Devices;
  2. CT scan equipment;
  3. MRI equipment;
  4. Defibrillators;
  5. PET Equipment;
  6. Dialysis Machine;
  7. X-Ray Machine; and
  8. Bone marrow cell separator.

Accordingly, as per the said order the importers/manufacturers are required to take import/manufacturing licence from Central Licencing Authority or State Licencing Authority, as the case may be, for import/manufacture of above devices, w.e.f. 1st April, 2021.

In order to ensure  supply chain continuity and access to these Medical Devices, while implementing  smooth transition into the new regulatory regime, Union Ministry of Health and Family Welfare has now decided that in case an existing importer/manufacturer who is already importing /manufacturing any of these devices, has submitted application to Central Licencing Authority or State Licencing Authority, as the case may be, for grant of import /manufacturing licence in respect of the said device(s) under the provisions of MDR, 2017, the said application shall be deemed valid and the importer/manufacturer can continue to import /manufacture the said device(s) up to 6 months from issue of this order or till the time, the Central Licencing Authority or State Licencing Authority, as the case may be, takes a decision on the said application, whichever is earlier. Order in this regard has been issued by Drugs Controller General (India) on 18th April 2021 through CDSCO website.

[pdf-embedder url=”https://medicarepharmabusiness.com/wp-content/uploads/2021/04/MDnotice18-190421073032.pdf”]

  • Related Posts

    Dr Reddy’s delays semaglutide supplies due to API issue

    MUMBAI: Dr Reddy’s Laboratories’ plans to capitalize on the early generic semaglutide market have hit a setback after manufacturing issues delayed supplies of the blockbuster diabetes and weight-loss drug, forcing…

    India Tightens Rules On Alcohol-Containing Medicines

    New rules on alcohol in medicine: The Centre has brought oral medicines containing more than 12% ethyl alcohol and sold in bottles larger than 30 ml under Schedule H1 In…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Dr Reddy’s delays semaglutide supplies due to API issue

    Dr Reddy’s delays semaglutide supplies due to API issue

    India Tightens Rules On Alcohol-Containing Medicines

    India Tightens Rules On Alcohol-Containing Medicines

    One more held in spurious plasma racket; police say he supplied 12 boxes

    One more held in spurious plasma racket; police say he supplied 12 boxes

    Wegovy, Ozempic regain weight as Indian generics fall behind

    Wegovy, Ozempic regain weight as Indian generics fall behind

    Drug regulator orders fresh safety labels for five common antimicrobials

    Drug regulator orders fresh safety labels for five common antimicrobials

    Rajasthan recalls labour-inducing drug after quality test failure

    Rajasthan recalls labour-inducing drug after quality test failure